James Buchanan MA
- Learning Disabilities
- Buchanan James, Wordsworth Sarah, and Schuh Anna (2013) Issues surrounding the health economic evaluation of genomic technologies. Pharmacogenomics, 14(15):1833-47.
- Buchanan James, Wordsworth Sarah, Ahmad Tariq, Perrin Angela, Vermeire Severine, Sans Miquel, Taylor Jenny, and Jewell Derek (2011) Managing the long term care of inflammatory bowel disease patients: The cost to European health care providers. J Crohns Colitis, 5(4):301-16.
- Buchanan James, Mihaylova Borislava, Gray Alastair, and White Nicholas (2010) Cost-Effectiveness of Pre-Referral Antimalarial, Antibacterial, and Combined Rectal Formulations for Severe Febrile Illness PLoS ONE, 5(12):e14446.
- Wordsworth S, Buchanan J, Papanicolas I, Taylor J, Frayling I, and Tomlinson I (2008) Molecular Testing for Somatic Mutations in Common Cancers: The views of UK Oncologists. Journal of Clinical Pathology, 61:761-765.
- Wordsworth S, Buchanan J, Regan R, Davison V, Smith K, Dyer S, Campbell C, Blair E, Maher E, Taylor J, and Knight S J (2007) Diagnosing ideopathic learning disability: A cost-effectiveness anaylsis of microarray technology in the National Health Service of the United Kingdom Genomic Medicine, 1:35-45.
|Tel||+44 (0)1865 289 262|
|Fax||+44 (0)1865 289 271|
James Buchanan joined the Health Economics Research Centre in September 2005, having completed his MA in Economic Development and Policy Analysis and his BA in Economics at the University of Nottingham. James is currently working on a number of genetics projects, which include an economic evaluation of the use of genetic testing to identify the somatic mutations that can cause common cancers. Other genetics projects currently underway include economic evaluations of high resolution genetic testing for chronic lymphocytic leukaemia, and of the use of genetic tests to identify gastrointestinal pathogens to improve hospital infection control practice. Previous genetics projects have included the development of an economic modelling framework to evaluate novel genomic diagnostic tools in inflammatory bowel disease, and a cost-effectiveness analysis of microarray technology in the NHS. James is currently undertaking a DPhil (PhD) investigating issues related to the economic analysis of genomic diagnostic technologies for multifactorial genetic diseases in the UK NHS, based on a study evaluating a targeted array in haematological cancers.
In addition to his genetics research, James has studied the economic case for a combined antimalarial-antibacterial rectal formulation for community use in patients with severe malaria and bacterial infections, and has undertaken an economic analysis of a randomised controlled trial of several first-line treatments for the management of unexplained infertility. He has also contributed to a systematic review of relevant health economic studies to NICE clinical guideline on physical activity, play and sport for pre-school and school age children.